Gastrointestinal bleeding in the setting of anticoagulation and antiplatelet therapy

Journal of Clinical Gastroenterology

Volumn 43, Issue 1, 2009, Pages 5-12

  Barada, Kassem ^a   Abdul Baki, Heitham ^a   El Hajj, Ihab I ^a   Hashash, Jana G ^a   Green, Peter H ^b  

^a AMERICAN UNIVERSITY OF BEIRUT   (Lebanon)

^b Columbia University College of Physicians and Surgeons ^*  (United States)

Author keywords

Anticoagulation; Antiplatelet; Gastrointestinal bleeding

Indexed keywords

ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; ANTITHROMBOCYTIC AGENT; BLOOD CLOTTING FACTOR 7; CLOPIDOGREL; CORTICOSTEROID; FRESH FROZEN PLASMA; HEPARIN; LOW MOLECULAR WEIGHT HEPARIN; NONSTEROID ANTIINFLAMMATORY AGENT; OMEPRAZOLE; PHYTOMENADIONE; PLACEBO; PROTAMINE; PROTHROMBIN COMPLEX; PROTON PUMP INHIBITOR; RANITIDINE; VITAMIN K GROUP; WARFARIN;

ANEMIA; ANTICOAGULATION; CLINICAL TRIAL; COLON CANCER; COMORBIDITY; DIGESTIVE SYSTEM ULCER; DRUG HALF LIFE; DRUG MECHANISM; DRUG MEGADOSE; DRUG WITHDRAWAL; ENDOSCOPY; GASTROINTESTINAL HEMORRHAGE; HEART ATRIUM FIBRILLATION; HEMOSTASIS; HISTOPATHOLOGY; HUMAN; IRON DEFICIENCY; IRON DEFICIENCY ANEMIA; LOW DRUG DOSE; MEDICAL LITERATURE; OCCULT BLOOD TEST; PEPTIC ULCER; PRIORITY JOURNAL; PROPHYLAXIS; REVIEW; RISK FACTOR; STROKE; THROMBOEMBOLISM; TREATMENT OUTCOME; UPPER GASTROINTESTINAL BLEEDING;

ANTICOAGULANTS; CLINICAL TRIALS AS TOPIC; ENDOSCOPY; GASTROINTESTINAL HEMORRHAGE; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; HUMANS; PLATELET AGGREGATION INHIBITORS; PROTON PUMP INHIBITORS; RISK FACTORS;

EID: 67651180738     PISSN: 01920790     EISSN: None     Source Type: Journal    
DOI: 10.1097/MCG.0b013e31811edd13     Document Type: Review

References (110)

1. Strate LL. Lower GI bleeding: epidemiology and diagnosis. Gastroenterol Clin North Am. 2005;34:643-664.
2. Targownik LE, Nabalamba A. Trends in management and outcomes of acute nonvariceal upper gastrointestinal bleeding: 1993-2003. Clin Gastroenterol Hepatol. 2006;4:1459-1466.
3. van Leerdam ME, Vreeburg EM, Rauws EA, et al. Acute upper GI bleeding: did anything change? Time trend analysis of incidence and outcome of acute upper GI bleeding between 1993/1994 and 2000. Am J Gastroenterol. 2003;98:1494-1499.
4. Dulai GS, Gralnek IM, Oei TT, et al. Utilization of health care resources for low-risk patients with acute, nonvariceal upper GI hemorrhage: an historical cohort study. Gastrointest Endosc. 2002;55:321-327.
5. Johnsen SP, Sorensen HT, Mellemkjoer L, et al. Hospitalisation for upper gastrointestinal bleeding associated with use of oral anticoagulants. Thromb Haemost. 2001;86:563-568.
6. Wolf AT, Wasan SK, Saltzman JR. Impact of anticoagulation on rebleeding following endoscopic therapy for nonvariceal upper gastrointestinal hemorrhage. Am J Gastroenterol. 2007;102:290-296.
7. Ibanez L, Vidal X, Vendrell L, et al. Upper gastrointestinal bleeding associated with antiplatelet drugs. Aliment Pharmacol Ther. 2006;23:235-242.
8. Pirmohamed M, James S, Meakin S, et al. Adverse drug reactions as cause of admission to hospital: prospective analysis of 18 820 patients. BMJ. 2004;329:15-19.
9. Strate LL, Orav EJ, Syngal S. Early predictors of severity in acute lower intestinal tract bleeding. Arch Intern Med. 2003; 163:838-843.
10. Taha AS, Angerson WJ, Knill-Jones RP, et al. Clinical outcome in upper gastrointestinal bleeding complicating lowdose aspirin and antithrombotic drugs. Aliment Pharmacol Ther. 2006;24:633-636.
11. Harder S, Klinkhardt U, Alvarez JM. Avoidance of bleeding during surgery in patients receiving anticoagulant and/or antiplatelet therapy: pharmacokinetic and pharmacodynamic considerations. Clin Pharmacokinet. 2004;43:963-981.
12. Rockey DC. Occult gastrointestinal bleeding. Gastroenterol Clin North Am. 2005;34:699-718.
13. Boland CR. Malignant tumors of the colon. In: Yamada T, ed. Textbook of Gastroenterology. Vol 2. 4th ed. Philadelphia: Lippincott Williams & Wilkins; 2003:1940-1990.
14. Rockey DC. Occult gastrointestinal bleeding. N Engl J Med. 1999;341:38-46.
15. Levin B, Hess K, Johnson C. Screening for colorectal cancer. A comparison of 3 fecal occult blood tests. Arch Intern Med. 1997;157:970-976.
16. Greenberg PD, Cello JP, Rockey DC. Asymptomatic chronic gastrointestinal blood loss in patients taking aspirin or warfarin for cardiovascular disease. Am J Med. 1996;100: 598-604.
17. Jaffin BW, Bliss CM, LaMont JT. Significance of occult gastrointestinal bleeding during anticoagulation therapy. Am J Med. 1987;83:269-272.
18. Prichard PJ, Kitchingman GK, Walt RP, et al. Human gastric mucosal bleeding induced by low dose aspirin, but not warfarin. BMJ. 1989;298:493-496.
19. Bini EJ, Rajapaksa RC, Weinshel EH. Positive predictive value of fecal occult blood testing in persons taking warfarin. Am J Gastroenterol. 2005;100:1586-1592.
20. Greenberg PD, Cello JP, Rockey DC. Relationship of lowdose aspirin to GI injury and occult bleeding: a pilot study. Gastrointest Endosc. 1999;50:618-622.
21. Kahi CJ, Imperiale TF. Do aspirin and nonsteroidal antiinflammatory drugs cause false-positive fecal occult blood test results? A prospective study in a cohort of veterans. Am J Med. 2004;117:837-841.
22. Hurlen M, Eikvar L, Seljeflot I, et al. Occult bleeding in three different antithrombotic regimes after myocardial infarction. A WARIS-II subgroup analysis. Thromb Res. 2006;118:433-438.
23. James MW, Chen CM, Goddard WP, et al. Risk factors for gastrointestinal malignancy in patients with iron-deficiency anaemia. Eur J Gastroenterol Hepatol. 2005;17:1197-1203.
24. Lanas A, Garcia-Rodriguez LA, Arroyo MT, et al. Risk of upper gastrointestinal ulcer bleeding associated with selective cyclo-oxygenase-2 inhibitors, traditional non-aspirin nonsteroidal anti-inflammatory drugs, aspirin, and combinations. Gut. 2006;55:1731-1738.
25. McQuaid KR, Laine L. Systematic review and meta-analysis of adverse events of low-dose aspirin and clopidogrel in randomized controlled trials. Am J Med. 2006;119:624-638.
26. Patrono C, Garcia Rodriguez LA, Landolfi R, et al. Lowdose aspirin for the prevention of atherothrombosis. N Engl J Med. 2005;353:2373-2383.
27. Silagy CA, McNeil JJ, Donnan GA, et al. Adverse effects of low-dose aspirin in a healthy elderly population. Clin Pharmacol Ther. 1993;54:84-89.
28. Laine L. Review article: gastrointestinal bleeding with lowdose aspirin-what's the risk? Aliment Pharmacol Ther. 2006; 24:897-908.
29. Ridker PM, Cook NR, Lee IM, et al. A randomized trial of low-dose aspirin in the primary prevention of cardiovascular disease in women. N Engl J Med. 2005;352: 1293-1304.
30. Sam C, Massaro JM, D'Agostino RB Sr, et al. Warfarin and aspirin use and the predictors of major bleeding complications in atrial fibrillation (the Framingham Heart Study). Am J Cardiol. 2004;94:947-951.
31. Ng W, Wong WM, Chen WH, et al. Incidence and predictors of upper gastrointestinal bleeding in patients receiving lowdose aspirin for secondary prevention of cardiovascular events in patients with coronary artery disease. World J Gastroenterol. 2006;12:2923-2927.
32. Mangano DT. Aspirin and mortality from coronary bypass surgery. N Engl J Med. 2002;347:1309-1317.
33. Lanas A, Bajador E, Serrano P, et al. Nitrovasodilators, lowdose aspirin, other nonsteroidal antiinflammatory drugs, and the risk of upper gastrointestinal bleeding. N Engl J Med. 2000; 343:834-839.
34. Battistella M, Mamdami MM, Juurlink DN, et al. Risk of upper gastrointestinal hemorrhage in warfarin users treated with nonselective NSAIDs or COX-2 inhibitors. Arch Intern Med. 2005;165:189-192.
35. Nielsen GL, Sorensen HT, Mellemkjoer L, et al. Risk of hospitalization resulting from upper gastrointestinal bleeding among patients taking corticosteroids: a register-based cohort study. Am J Med. 2001;111:541-545.
36. Kaufman DW, Kelly JP, Wiholm BE, et al. The risk of acute major upper gastrointestinal bleeding among users of aspirin and ibuprofen at various levels of alcohol consumption. Am J Gastroenterol. 1999;94:3189-3196.
37. Landefeld CS, Cook EF, Flatley M, et al. Identification and preliminary validation of predictors of major bleeding in hospitalized patients starting anticoagulant therapy. Am J Med. 1987;82:703-713.
38. Sorensen HT, Mellemkjaer L, Blot WJ, et al. Risk of upper gastrointestinal bleeding associated with use of low-dose aspirin. Am J Gastroenterol. 2000;95:2218-2224.
39. Weil J, Langman MJ, Wainwright P, et al. Peptic ulcer bleeding: accessory risk factors and interactions with nonsteroidal anti-inflammatory drugs. Gut. 2000;46:27-31.
40. CAPRIE Steering Committee. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet. 1996;348:1329-1339.
41. Harker LA, Boissel JP, Pilgrim AJ, et al. Comparative safety and tolerability of clopidogrel and aspirin: results from CAPRIE. CAPRIE Steering Committee and Investigators. Clopidogrel versus aspirin in patients at risk of ischaemic events. Drug Safety. 1999;21:325-335.
42. Liberopoulos EN, Elisaf MS, Tselepis AD, et al. Upper gastrointestinal haemorrhage complicating antiplatelet treatment with aspirin and/or clopidogrel: where we are now? Platelets. 2006;17:1-6.
43. Ezekowitz MD, Bridgers SL, James KE, et al. Warfarin in the prevention of stroke associated with nonrheumatic atrial fibrillation. Veterans Affairs Stroke Prevention in Nonrheumatic Atrial Fibrillation Investigators. N Engl J Med. 1992; 327:1406-1412.
44. Levine MN, Raskob G, Beyth RJ, et al. Hemorrhagic complications of anticoagulant treatment: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest. 2004;126:287S-310S.
45. Palareti G, Leali N, Coccheri S, et al. Bleeding complications of oral anticoagulant treatment: an inception-cohort, prospective collaborative study (ISCOAT). Italian Study on Complications of Oral Anticoagulant Therapy. Lancet. 1996; 348:423-428.
46. Shireman TI, Mahnken JD, Howard PA, et al. Development of a contemporary bleeding risk model for elderly warfarin recipients. Chest. 2006;130:1390-1396.
47. Petty GW, Brown RD Jr, Whisnant JP, et al. Frequency of major complications of aspirin, warfarin, and intravenous heparin for secondary stroke prevention. A population-based study. Ann Intern Med. 1999;130:14-22.
48. Levine MN, Raskob G, Landefeld S, et al. Hemorrhagic complications of anticoagulant treatment. Chest. 2001;119: 108S-121S.
49. Landefeld CS, Beyth RJ. Anticoagulant-related bleeding: clinical epidemiology, prediction, and prevention. Am J Med. 1993;95:315-328.
50. Harenberg J, Huhle G, Piazolo L, et al. Long-term anticoagulation of outpatients with adverse events to oral anticoagulants using low-molecular-weight heparin. Semin Thromb Hemost. 1997;23:167-172.
51. Hallas J, Dall M, Andries A, et al. Use of single and combined antithrombotic therapy and risk of serious upper gastrointestinal bleeding: population based case-control study. BMJ. 2006;333:726.
52. Diener HC, Bogousslavsky J, Brass LM, et al. Aspirin and clopidogrel compared with clopidogrel alone after recent ischaemic stroke or transient ischaemic attack in high-risk patients (MATCH): randomised, double-blind, placebo-controlled trial. Lancet. 2004;364:331-337.
53. Yusuf S, Mehta SR, Zhao F, et al. Early and late effects of clopidogrel in patients with acute coronary syndromes. Circulation. 2003;107:966-972.
54. Turpie AG, Gent M, Laupacis A, et al. A comparison of aspirin with placebo in patients treated with warfarin after heart-valve replacement. N Engl J Med. 1993;329:524-529.
55. Hurlen M, Abdelnoor M, Smith P, et al. Warfarin, aspirin, or both after myocardial infarction. N Engl J Med. 2002;347: 969-974.
56. Barada K, Karrowni W, Abdallah M, et al. Upper gastrointestinal bleeding in patients with acute coronary syndromes: clinical predictors and role of proton pump inhibitors. J Clin Gastroenterol. 2007. In press.
57. Atar S, Cannon CP, Murphy SA, et al. Statins are associated with lower risk of gastrointestinal bleeding in patients with unstable coronary syndromes: analysis of the Orbofiban in Patients with Unstable coronary Syndromes-Thrombolysis In Myocardial Infarction 16 (OPUS-TIMI 16) trial. Am Heart J. 2006;151:976e1-6
58. Popma JJ, Berger P, Ohman EM, et al. Antithrombotic therapy during percutaneous coronary intervention: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest. 2004;126:576S-599S.
59. Silber S, Albertsson P, Aviles FF, et al. Guidelines for percutaneous coronary interventions. The Task Force for Percutaneous Coronary Interventions of the European Society of Cardiology. Eur Heart J. 2005;26:804-847.
60. Smith SC Jr, Feldman TE, Hirshfeld JW Jr, et al. ACC/AHA/ SCAI 2005 Guideline Update for Percutaneous Coronary Intervention-summary article: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (ACC/AHA/SCAI Writing Committee to Update the 2001 Guidelines for Percutaneous Coronary Intervention). Circulation. 2006;113:156-175.
61. Artang R, Dieter RS. Analysis of 36 reported cases of late thrombosis in drug-eluting stents placed in coronary arteries. Am J Cardiol. 2007;99:1039-1043.
62. Eisenstein EL, Anstrom KJ, Kong DF, et al. Clopidogrel use and long-term clinical outcomes after drug-eluting stent implantation. JAMA. 2007;297:159-168.
63. Lagerqvist B, James SK, Stenestrand U, et al. Long-term outcomes with drug-eluting stents versus bare-metal stents in Sweden. N Engl J Med. 2007;356:1009-1019.
64. Park DW, Park SW, Park KH, et al. Frequency of and risk factors for stent thrombosis after drug-eluting stent implantation during long-term follow-up. Am J Cardiol. 2006;98:352-356.
65. Ng FH, Wong SY, Chang CM, et al. High incidence of clopidogrel-associated gastrointestinal bleeding in patients with previous peptic ulcer disease. Aliment Pharmacol Ther. 2003;18:443-449.
66. Yusuf S, Zhao F, Mehta SR, et al. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med. 2001;345:494-502.
67. Peters RJ, Mehta SR, Fox KA, et al. Effects of aspirin dose when used alone or in combination with clopidogrel in patients with acute coronary syndromes: observations from the Clopidogrel in Unstable angina to prevent Recurrent Events (CURE) study. Circulation. 2003;108:1682-1687.
68. Smith SC Jr, Feldman TE, Hirshfeld JW Jr, et al. ACC/AHA/ SCAI 2005 Guideline Update for Percutaneous Coronary Intervention-Summary Article: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (ACC/AHA/SCAI Writing Committee to Update the 2001 Guidelines for Percutaneous Coronary Intervention). J Am Coll Cardiol. 2006;47:216-235.
69. Lip GY, Karpha M. Anticoagulant and antiplatelet therapy use in patients with atrial fibrillation undergoing percutaneous coronary intervention: the need for consensus and a management guideline. Chest. 2006;130:1823-1827.
70. Porter A, Konstantino Y, Iakobishvili Z, et al. Short-term triple therapy with aspirin, warfarin, and a thienopyridine among patients undergoing percutaneous coronary intervention. Catheter Cardiovasc Interv. 2006;68:56-61.
71. Rubboli A, Colletta M, Herzfeld J, et al. Periprocedural and medium-term antithrombotic strategies in patients with an indication for long-term anticoagulation undergoing coronary angiography and intervention. Coron Artery Dis. 2007;18: 193-199.
72. Beyth RJ, Quinn LM, Landefeld CS. Prospective evaluation of an index for predicting the risk of major bleeding in outpatients treated with warfarin. Am J Med. 1998;105:91-99.
73. Blatchford O, Murray WR, Blatchford M. A risk score to predict need for treatment for upper-gastrointestinal haemorrhage. Lancet. 2000;356:1318-1321.
74. Choudari CP, Rajgopal C, Palmer KR. Acute gastrointestinal haemorrhage in anticoagulated patients: diagnoses and response to endoscopic treatment. Gut. 1994;35:464-466.
75. Rubin TA, Murdoch M, Nelson DB. Acute GI bleeding in the setting of supratherapeutic international normalized ratio in patients taking warfarin: endoscopic diagnosis, clinical management, and outcomes. Gastrointest Endosc. 2003;58: 369-373.
76. Wilcox CM, Truss CD. Gastrointestinal bleeding in patients receiving long-term anticoagulant therapy. Am J Med. 1988; 84:683-690.
77. Tabibian N. Acute gastrointestinal bleeding in anticoagulated patients: a prospective evaluation. Am J Gastroenterol. 1989; 84:10-12.
78. Taha AS, Angerson WJ, Knill-Jones RP, et al. Upper gastrointestinal mucosal abnormalities and blood loss complicating low-dose aspirin and antithrombotic therapy. Aliment Pharmacol Ther. 2006;23:489-495.
79. Thomopoulos KC, Mimidis KP, Theocharis GJ, et al. Acute upper gastrointestinal bleeding in patients on long-term oral anticoagulation therapy: endoscopic findings, clinical management and outcome. World J Gastroenterol. 2005;11:1365-1368.
80. Choudari CP, Palmer KR. Acute gastrointestinal haemorrhage in patients treated with anticoagulant drugs. Gut. 1995;36: 483-484.
81. Qvigstad G, Hatlen-Rebhan P, Brenna E, et al. Capsule endoscopy in clinical routine in patients with suspected disease of the small intestine: a 2-year prospective study. Scand J Gastroenterol. 2006;41:614-618.
82. Baker RI, Coughlin PB, Gallus AS, et al. Warfarin reversal: consensus guidelines, on behalf of the Australasian Society of Thrombosis and Haemostasis. Med J Aust. 2004;181:492-497.
83. White RH, McKittrick T, Takakuwa J, et al. Management and prognosis of life-threatening bleeding during warfarin therapy. National Consortium of Anticoagulation Clinics. Arch Intern Med. 1996;156:1197-1201.
84. Makar GA, Ginsberg GG. Therapy insight: approaching endoscopy in anticoagulated patients. Nat Clin Pract Gastroenterol Hepatol. 2006;3:43-52.
85. Baglin TP, Keeling DM, Watson HG. Guidelines on oral anticoagulation (warfarin): third edition-2005 update. Br J Haematol. 2006;132:277-285.
86. Ananthasubramaniam K, Beattie JN, Rosman HS, et al. How safely and for how long can warfarin therapy be withheld in prosthetic heart valve patients hospitalized with a major hemorrhage? Chest. 2001;119:478-484.
87. Kuwada SK, Balm R, Gostout CJ. The risk of withdrawing chronic anticoagulation because of acute GI bleeding. Am J Gastroenterol. 1996;91:1116-1119.
88. Blacker DJ, Wijdicks EF, McClelland RL. Stroke risk in anticoagulated patients with atrial fibrillation undergoing endoscopy. Neurology. 2003;61:964-968.
89. Lubetsky A, Yonath H, Olchovsky D, et al. Comparison of oral vs intravenous phytonadione (vitamin K1) in patients with excessive anticoagulation: a prospective randomized controlled study. Arch Intern Med. 2003;163:2469-2473.
90. Sconce EA, Kamali F. Appraisal of current vitamin K dosing algorithms for the reversal of over-anticoagulation with warfarin: the need for a more tailored dosing regimen. Eur J Haematol. 2006;77:457-462.
91. Dager WE, King JH, Regalia RC, et al. Reversal of elevated international normalized ratios and bleeding with low-dose recombinant activated factor VII in patients receiving warfarin. Pharmacotherapy. 2006;26:1091-1098.
92. Ingerslev J, Vanek T, Culic S. Use of recombinant factor VIIa for emergency reversal of anticoagulation. J Postgrad Med. 2007;53:17-22.
93. Lankiewicz MW, Hays J, Friedman KD, et al. Urgent reversal of warfarin with prothrombin complex concentrate. J Thromb Haemost. 2006;4:967-970.
94. van Aart L, Eijkhout HW, Kamphuis JS, et al. Individualized dosing regimen for prothrombin complex concentrate more effective than standard treatment in the reversal of oral anticoagulant therapy: an open, prospective randomized controlled trial. Thromb Res. 2006;118:313-320.
95. Fiore LD, Scola MA, Cantillon CE, et al. Anaphylactoid reactions to vitamin K. J Thromb Thrombolysis. 2001;11: 175-183.
96. Cameron EA, Pratap JN, Sims TJ, et al. Three-year prospective validation of a pre-endoscopic risk stratification in patients with acute upper-gastrointestinal haemorrhage. Eur J Gastroenterol Hepatol. 2002;14:497-501.
97. Strate LL, Saltzman JR, Ookubo R, et al. Validation of a clinical prediction rule for severe acute lower intestinal bleeding. Am J Gastroenterol. 2005;100:1821-1827.
98. Jensen DM, Cheng S, Kovacs TO, et al. A controlled study of ranitidine for the prevention of recurrent hemorrhage from duodenal ulcer. N Engl J Med. 1994;330:382-386.
99. Lai KC, Lam SK, Chu KM, et al. Lansoprazole for the prevention of recurrences of ulcer complications from longterm low-dose aspirin use. N Engl J Med. 2002;346:2033-2038.
100. Lanas A, Fuentes J, Benito R, et al. Helicobacter pylori increases the risk of upper gastrointestinal bleeding in patients taking low-dose aspirin. Aliment Pharmacol Ther. 2002;16: 779-786.
101. Chan FK, Chung SC, Suen BY, et al. Preventing recurrent upper gastrointestinal bleeding in patients with Helicobacter pylori infection who are taking low-dose aspirin or naproxen. N Engl J Med. 2001;344:967-973.
102. Ng FH, Wong BC, Wong SY, et al. Clopidogrel plus omeprazole compared with aspirin plus omeprazole for aspirin-induced symptomatic peptic ulcers/erosions with low to moderate bleeding/re-bleeding risk-a single-blind, randomized controlled study. Aliment Pharmacol Ther. 2004;19: 359-365.
103. Chan FK, Ching JY, Hung LC, et al. Clopidogrel versus aspirin and esomeprazole to prevent recurrent ulcer bleeding. N Engl J Med. 2005;352:238-244.
104. Lanas A. Prevention of aspirin-induced gastroduodenal damage: H. pylori infection eradication versus proton pump inhibitors or both. Dig Liver Dis. 2004;36:655-657.
105. Lanas A, Rodrigo L, Marquez JL, et al. Low frequency of upper gastrointestinal complications in a cohort of high-risk patients taking low-dose aspirin or NSAIDs and omeprazole. Scand J Gastroenterol. 2003;38:693-700.
106. Pilotto A, Franceschi M, Longoa MG, et al. Helicobacter pylori infection and the prevention of peptic ulcer with proton pump inhibitors in elderly subjects taking low-dose aspirin. Dig Liver Dis. 2004;36:666-670.
107. Cryer B. Reducing the risks of gastrointestinal bleeding with antiplatelet therapies. N Engl J Med. 2005;352:287-289.
108. Younossi ZM, Strum WB, Schatz RA, et al. Effect of combined anticoagulation and low-dose aspirin treatment on upper gastrointestinal bleeding. Dig Dis Sci. 1997;42: 79-82.
109. Kimmey MB. Cardioprotective effects and gastrointestinal risks of aspirin: maintaining the delicate balance. Am J Med. 2004;117(suppl 5A):72S-78S.
110. Blackshear JL, Baker VS, Holland A, et al. Fecal hemoglobin excretion in elderly patients with atrial fibrillation: combined aspirin and low-dose warfarin vs conventional warfarin therapy. Arch Intern Med. 1996;156:658-660.